EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

Natthawadee Laokulrath, Mihir Gudi, Syed Ahmed Salahuddin, Angela Phek Yoon Chong, Cristine Ding, Jabed Iqbal iD, Wei Qiang Leow, Benjamin Yongcheng Tan iD, Gary Tse, Emad Rakha iD, Puay Hoon Tan iD

Histopathology · 2024-09 · 85 (3) · 371-382

DOI: 10.1111/his.15213 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Histopathology, online erschienen am 06.06.2024. Verfasst von Natthawadee Laokulrath und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Biomarkers, Tumor. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2)‐enriched breast cancer benefits significantly from anti‐HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti‐HER2 regimens. Recently, the emerging eligibility of patients with HER2‐low breast cancers for a novel HER2‐targeted antibody–drug conjugate (T‐DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0–1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunohistochemistryBiomarkers, TumorHumansFemale

Stichwörter der Autor:innen

HER2HER2 scoringHER2‐lowbreast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore.
  • Department of Anatomical Pathology, Singapore General Hospital, Singapore.
  • Department of Pathology, Sengkang General Hospital, Singapore.
  • Division of Anatomical Pathology, Changi General Hospital, Singapore.
  • Duke-NUS Medical School, Singapore.

ORCID-Profile: Jabed Iqbal, Benjamin Yongcheng Tan, Emad Rakha, Puay Hoon Tan

Zitieren

APA

Laokulrath, N., Gudi, M., Salahuddin, S. A., Chong, A. P. Y., Ding, C., Iqbal, J., Leow, W. Q., Tan, B. Y., Tse, G., Rakha, E., & Tan, P. H. (2024). Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges. Histopathology, 85(3), 371-382. https://doi.org/10.1111/his.15213

Vancouver

Laokulrath N, Gudi M, Salahuddin SA, Chong APY, Ding C, Iqbal J, et al. Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges. Histopathology. 2024;85(3):371-382. doi:10.1111/his.15213

BibTeX
@article{Laokulrath2024,
  author = {Laokulrath, Natthawadee and Gudi, Mihir and Salahuddin, Syed Ahmed and Chong, Angela Phek Yoon and Ding, Cristine and Iqbal, Jabed and Leow, Wei Qiang and Tan, Benjamin Yongcheng and Tse, Gary and Rakha, Emad and Tan, Puay Hoon},
  title = {Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges},
  journal = {Histopathology},
  year = {2024},
  volume = {85},
  number = {3},
  pages = {371--382},
  doi = {10.1111/his.15213}
}
Kostenlos starten →